Aldeyra Therapeutics, Inc. - Common Stock (ALDX)

CUSIP: 01438T106

Q1 2017 13F Holders as of 31 Mar 2017

Type / Class
Equity / Common Stock
Shares outstanding
59,794,743
Total 13F shares
7,897,813
Share change
+1,792,949
Total reported value
$37,958,000
Price per share
$5.00
Number of holders
24
Value change
+$8,366,763
Number of buys
16
Number of sells
6

Quarterly Holders Quick Answers

What is CUSIP 01438T106?
CUSIP 01438T106 identifies ALDX - Aldeyra Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of ALDX - Aldeyra Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
PERCEPTIVE ADVISORS LLC
13F
Company
3.2%
1,940,458
$10,381,000 31 Dec 2016
13F
FMR LLC
13F
Company
3%
1,797,811
$9,618,000 31 Dec 2016
13F
AWM Investment Company, Inc.
13F
Company
1.5%
912,610
$4,882,000 31 Dec 2016
13F
SPHERA FUNDS MANAGEMENT LTD.
13F
Company
0.62%
368,500
$1,971,000 31 Dec 2016
13F
Boxer Capital, LLC
13F
Company
0.49%
291,230
$1,558,000 31 Dec 2016
13F
VANGUARD GROUP INC
13F
Company
0.24%
145,472
$779,000 31 Dec 2016
13F
BAKER BROS. ADVISORS LP
13F
Company
0.24%
142,000
$760,000 31 Dec 2016
13F
Knoll Capital Management, LLC
13F
Company
0.23%
135,800
$727,000 31 Dec 2016
13F
PURA VIDA INVESTMENTS, LLC
13F
Company
0.21%
125,000
$669,000 31 Dec 2016
13F
MILLENNIUM MANAGEMENT LLC
13F
Company
0.17%
100,000
$535,000 31 Dec 2016
13F
Weiss Multi-Strategy Advisers LLC
13F
Company
0.11%
65,000
$348,000 31 Dec 2016
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.09%
52,976
$283,000 31 Dec 2016
13F
BlackRock Fund Advisors
13F
Company
0.05%
27,319
$146,000 31 Dec 2016
13F
NORTHERN TRUST CORP
13F
Company
0.02%
14,324
$77,000 31 Dec 2016
13F
BANK OF AMERICA CORP /DE/
13F
Company
0.01%
6,000
$32,000 31 Dec 2016
13F
Tower Research Capital LLC (TRC)
13F
Company
0.01%
3,760
$20,000 31 Dec 2016
13F
MORGAN STANLEY
13F
Company
0%
2,982
$16,000 31 Dec 2016
13F
BLACKROCK ADVISORS LLC
13F
Company
0%
2,978
$16,000 31 Dec 2016
13F
BlackRock Investment Management, LLC
13F
Company
0%
1,457
$8,000 31 Dec 2016
13F
MANUFACTURERS LIFE INSURANCE COMPANY, THE
13F
Company
0%
941
$5,000 31 Dec 2016
13F

Institutional Holders of Aldeyra Therapeutics, Inc. - Common Stock (ALDX) as of Q1 2017

As of 31 Mar 2017, Aldeyra Therapeutics, Inc. - Common Stock (ALDX) was held by 24 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 7,897,813 shares. The largest 10 holders included PERCEPTIVE ADVISORS LLC, FMR LLC, AWM Investment Company, Inc., SPHERA FUNDS MANAGEMENT LTD., ADAGE CAPITAL PARTNERS GP, L.L.C., VANGUARD GROUP INC, Boxer Capital, LLC, SABBY MANAGEMENT, LLC, Knoll Capital Management, LP, and MILLENNIUM MANAGEMENT LLC. This page lists 24 institutional shareholders reporting positions in this security for the Q1 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q1 2017 vs Q4 2016 Across Filers

Q4 2016 holders
20
Q1 2017 holders
24
Holder diff
4
Investor Q4 2016 Shares Q1 2017 Shares Share Diff Share Chg % Q4 2016 Value $ Q1 2017 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .